Shaman Pharmaceuticals promotes Gerald M. Reaven to Senior Vice President.
SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--Feb. 14, 1996--Shaman Pharmaceuticals today announced that Gerald M. Reaven M.D. has been promoted to the position of senior vice president of research.
Reaven will continue to focus his efforts on identification of compounds for Shaman's clinical programs, with a current focus on the company's eight new compounds for non-insulin dependent diabetes mellitus (NIDDM NIDDM
non-insulin-dependent diabetes mellitus
non-insulin-dependent diabetes mellitus.
NIDDM Non-insulin-dependent diabetes mellitus. See Type 2 diabetes mellitus. ). He reports directly to Lisa Conte, Shaman's president and chief executive officer.
Reaven joined the company as vice president of research in July 1995. Prior to joining Shaman, Reaven was professor of medicine and headed the division of Endocrinology, Gerontology gerontology: see geriatrics. and Metabolism at Stanford University and directed the Geriatric Research, Education and Clinical Center at Palo Alto Veterans Affairs Medical Center. He has published numerous original scientific papers on various aspects of glucose, insulin, and lipoprotein metabolism and has received the highest awards for meritorious research from the American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of (Banting Award), the British Diabetes Association (Banting Award), the European Association for the Study of Diabetes (Claude Bernard Lectureship lec·ture·ship
1. The status or position of a lecturer.
2. An endowment or foundation supporting a series or course of lectures.
[Alteration of lecturership. ), and the American Diabetes Association, Indiana Affiliate (Josiah Kirby Lilly, Sr. Distinguished Service Award).
Lisa Conte, Shaman's president and chief executive officer, stated, "Jerry's many years of worldwide involvement in medicine and metabolic diseases have brought valuable wisdom and experience to Shaman's research team. This well-deserved promotion is a reflection of Jerry's hard work and commitment to Shaman."
In separate releases, the company also announced that Atul S. Khandwala Ph.D., will join Shaman as senior vice president of development and that Steven R. King Ph.D. has been promoted to senior vice president of ethnobotany ethnobotany /eth·no·bot·a·ny/ (-bot´ah-ne) the systematic study of the interactions between a culture and the plants in its environment, particularly the knowledge about and use of such plants. and conservation.
Shaman has three compounds in development. Virend, a topical antiviral for the treatment of herpes, is ready to begin pivotal Phase III testing. Provir, for the treatment of secretory secretory /se·cre·to·ry/ (se-kre´tah-re) (se´kre-tor?e) pertaining to secretion or affecting the secretions.
Relating to or performing secretion. diarrhea, is beginning Phase II trials. Nikkomycin-Z, an oral anti-fungal for the treatment of endemic mycosis mycosis: see fungal infection. , is expected to enter Phase I clinical testing in late 1996.
Shaman Pharmaceuticals uses an integrated approach to discover new chemical entities from tropical plants with a history of medicinal use. Shaman relies on ethnomedical investigation and sophisticated screening models which result in a more efficient drug discovery process. Shaman's diabetes program has resulted in the discovery of several distinct new chemical entities, and forms the basis for a collaborative relationship with Ono Pharmaceutical Co. Ltd. -0-
Note to Editors: Virend and Provir are trademarks of Shaman Pharmaceuticals, Inc.
CONTACT: Shaman Pharmaceuticals, Inc.
MaryAnne M. Hines, 415/952-7070, x481